Journal article Open Access

FORMULATION OPTIMIZATION AND IN-VITRO EVALUATION OF NANOSTRUCTURED LIPID CARRIER CONTAINING ANTIPSYCHOTIC DRUG

Arpita Nath*, Vilasrao Kadam

The main aim of the present work is to formulate, optimize and evaluate a Nanostructured Lipid Carrier (NLC) of a poorly water soluble antipsychotic drug: Ziprasidone hydrochloride monohydrate (ZHM) by high shear homogenization technique followed by ultrasonication method to enhance the oral bioavailability. ZHM a dopamine receptor antagonist, is an orally active atypical antipsychotic drug used in the treatment of schizophrenia and bipolar disorder. ZHM is a BCS Class II drug which is poorly water-soluble so its oral bioavailability is 60% when administered with food. The absorption of ZHM is increased up to two-fold in the presence of food. Preformulation studies including screening of excipients for solubility suggested the suitability of precirol ATO 5 as solid lipid, labrafil M1944 as liquid lipid and gelucire 50/13 as stabilizer for preparation of NLC. The optimized ZHM-NLC was characterised by measuring particle size, drug entrapment efficiency and in vitro drug release. The concentration of solid lipid and liquid lipid in the ratio of 70:30 was optimised as final formulation components concentration as it exhibited desired mean particle size (200-302 nm) and % Entrapment efficiency (54-84%). The in vitro drug release study indicated the ZHM-NLC sustained release formulation showed sustained release profile of 98.62 % release within 24 hours. Based on this results it was concluded that NLCs are promising drug delivery for improving the oral bioavailability of ZHM.

Files (1.5 MB)
Name Size
40.pdf
md5:1cd31f9fde1c5489326334e63598684c
1.5 MB Download
0
10
views
downloads
All versions This version
Views 017
Downloads 100
Data volume 14.9 MB0 Bytes
Unique views 016
Unique downloads 90

Share

Cite as